Webinar: A first technology for counting adult tissue stem cells for applications in regenerative medicine and drug development
Available to view on demand. Presenting a solution for the longstanding unsolved problem of quantifying the number of stem cells in research and therapeutic tissue cell preparations.
Since the first discovery of adult tissue stem cells, it has been impossible to count them. This conundrum persists because neither morphological nor molecular properties have been defined that distinguish tissue stem cells from more abundant committed progenitor cells. This webinar introduced AlphaSTEM, a first-in-class technology with the capability of counting homeostatic stem cells in complex research and therapeutic cell preparations from many different human tissues. The predicted impact of the AlphaSTEM stem cell counting technology on stem cell research, umbilical cord blood bank practice, hematopoietic stem cell transplantation therapies, gene-editing therapeutics, and drug candidate evaluations was considered.
What will you learn?
- The nature of the adult tissue stem cell counting problem
- How the AlphaSTEM stem cell counting technology works
- How stem cell counting will impact tissue stem cell research
the determination of “stem cell dose”, for the first time, will impact
stem cell transplantation medicine, gene-editing therapeutics, and
regenerative medicine research in general
the ability to count tissue stem cells has already enabled assays that
identify drug candidates that affect tissue stem cells, negatively,
positively, or both
Who may this interest?
- Research stem cell biologists, university and industry
- Preclinical drug candidate evaluation CROs
- Pharmaceutical companies (toxicologists, pharmacovigilance executives)
- Hematopoietic stem cell transplantation physicians
- Umbilical cord blood bank directors
- Gene-editing therapeutic companies
James L Sherley, MD, PhD
Founder and Director
James L Sherley is Director of stem cell medicine biotechnology company Asymmetrex, LLC. His education includes graduation from Harvard College in 1980 with a BA degree in Biology and from the Johns Hopkins University School of Medicine with combined MD/PhD degrees in 1988. After post-doctoral studies at Princeton University, he joined the Fox Chase Cancer Center as a principal investigator in 1991. His subsequent academic research career includes faculty positions at Massachusetts Institute of Technology and Boston Biomedical Research Institute. Dr Sherley’s research awards include Pew Biomedical Research Scholar, Ellison Medical Foundation Senior Scholar, and NIH Director’s Pioneer Award.
Additional Material from Asymmetrex
For a full list of other webinars available on RegMedNet please see here.